|
gptkbp:instanceOf
|
gptkb:anabolic_steroid
|
|
gptkbp:administeredBy
|
oral
intramuscular injection
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
|
|
gptkbp:CASNumber
|
10418-03-8
|
|
gptkbp:category
|
gptkb:veterinary_medicine
gptkb:synthetic_steroid
gptkb:androgen
performance-enhancing drug
anabolic agent
World Anti-Doping Agency prohibited substance
|
|
gptkbp:chemicalFormula
|
C21H32N2O
|
|
gptkbp:detects
|
gptkb:Ben_Johnson_(1988_Olympics)
|
|
gptkbp:developedBy
|
gptkb:Winthrop_Laboratories
|
|
gptkbp:introduced
|
1962
|
|
gptkbp:IUPACName
|
(17β)-17-hydroxy-2'H-androst-2-eno[3,2-c]pyrazol-17-yl acetate
|
|
gptkbp:legalStatus
|
Schedule III controlled substance in the United States
|
|
gptkbp:marketedAs
|
gptkb:Winstrol
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
328.5 g/mol
|
|
gptkbp:notableCase
|
gptkb:Lance_Armstrong_investigation
gptkb:Chris_Benoit_case
gptkb:Marion_Jones_doping_scandal
gptkb:Rafael_Palmeiro_suspension
|
|
gptkbp:sideEffect
|
hair loss
acne
voice changes
liver toxicity
increased risk of cardiovascular disease
|
|
gptkbp:used_in
|
athletes for performance enhancement
|
|
gptkbp:usedFor
|
gptkb:veterinary_medicine
treatment of anemia
treatment of hereditary angioedema
|
|
gptkbp:bfsParent
|
gptkb:anabolic_steroids
gptkb:Ben_Johnson_doping_scandal
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
stanozolol
|